Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / Fund iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker DRDR(GBX) LSE
ETF Ticker 2B78(EUR) F
ETF Ticker 2B78.DE(EUR) CXE
ETF Ticker DRDR.LS(GBX) CXE
ETF Ticker HEAL.AS(EUR) CXE
ETF Ticker HEAL.LS(USD) CXE
ETF Ticker HEALz(USD) CXE
ETF Ticker HEAL(EUR) ETF Plus
ETF Ticker DRDR.L(GBP) LSE

Holdings detail for SUPN

Stock Name	Supernus Pharmaceuticals Inc
Ticker	SUPN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8684591089
LEI	549300GRM36VBKISYJ58

Show aggregate SUPN holdings

News associated with SUPN

Contrasting Supernus Pharmaceuticals (NASDAQ:SUPN) and Evoke Pharma (NASDAQ:EVOK): Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) and Evoke Pharma (NASDAQ:EVOK – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility & Risk Supernus Pharmaceuticals has a beta […] - 2025-09-04 02:30:48
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Hold” at Zacks Research: Zacks Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Several other analysts also recently weighed in on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave […] - 2025-08-22 03:08:51
Maryland State Retirement & Pension System Trims Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Maryland State Retirement & Pension System lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,094 shares of the specialty pharmaceutical company’s stock after selling 2,514 shares during […] - 2025-08-15 04:51:00
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High on Analyst Upgrade: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s share price hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $42.00 to $46.00. Cantor Fitzgerald currently has an overweight rating on the stock. Supernus Pharmaceuticals traded as high as $41.51 and last traded at $42.29, with a […] - 2025-08-08 02:19:00
SUPN Crosses Above Average Analyst Target: In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $40.20, changing hands for $42.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-07 12:32:22
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen: Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Separately, Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price objective for the company in a […] - 2025-08-05 02:56:51
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen: Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday. Supernus Pharmaceuticals Stock Performance Shares of Supernus Pharmaceuticals stock opened at $33.23 on Friday. The firm has a fifty day moving average […] - 2025-07-22 02:55:51
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Allspring Global Investments Holdings LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,353 shares of the specialty pharmaceutical company’s stock after selling 1,356 shares during the quarter. […] - 2025-07-10 04:34:50
Robeco Institutional Asset Management B.V. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Robeco Institutional Asset Management B.V. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,151 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000. Other […] - 2025-07-03 05:08:49
Illinois Municipal Retirement Fund Has $927,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Illinois Municipal Retirement Fund decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,303 shares of the specialty pharmaceutical company’s stock after selling 730 shares […] - 2025-07-02 05:28:54
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Exchange Traded Concepts LLC: Exchange Traded Concepts LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.5% during the first quarter, HoldingsChannel reports. The firm owned 24,881 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,762 shares during the period. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $815,000 at […] - 2025-06-20 05:21:54
Azzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,847 shares of the specialty pharmaceutical company’s stock, valued at approximately $552,000. A number of other […] - 2025-06-16 05:40:53
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Versant Capital Management Inc: Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6,931.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,125 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-06-06 05:45:08
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 19,824 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 24.7% during the 4th quarter, Holdings Channel reports. The firm owned 100,020 shares of the specialty pharmaceutical company’s stock after buying an additional 19,824 shares during the period. UBS […] - 2025-06-05 05:10:54
Millennium Management LLC Sells 222,273 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Millennium Management LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 87.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,470 shares of the specialty pharmaceutical company’s stock after selling 222,273 shares during […] - 2025-06-05 04:25:01
Squarepoint Ops LLC Sells 475 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Squarepoint Ops LLC cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,492 shares of the specialty pharmaceutical company’s stock after selling 475 shares during the period. Squarepoint Ops LLC’s holdings in Supernus Pharmaceuticals were worth $741,000 at the end of […] - 2025-06-03 05:04:50
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,083 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,563 shares of the specialty pharmaceutical company’s stock after buying an additional 1,083 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Supernus Pharmaceuticals […] - 2025-05-26 04:47:00
Graham Capital Management L.P. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Graham Capital Management L.P. bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,908 shares of the specialty pharmaceutical company’s stock, valued at approximately $250,000. […] - 2025-05-19 05:26:49
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com: StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […] - 2025-05-19 02:38:47
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Northern Trust Corp: Northern Trust Corp boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 18.3% in the fourth quarter, HoldingsChannel reports. The firm owned 717,161 shares of the specialty pharmaceutical company’s stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp’s holdings in Supernus Pharmaceuticals were worth $25,933,000 as […] - 2025-05-12 04:49:02
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP: First Trust Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 48.1% in the 4th quarter, Holdings Channel reports. The firm owned 27,019 shares of the specialty pharmaceutical company’s stock after selling 25,048 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $977,000 […] - 2025-05-08 04:44:59
Barclays PLC Purchases 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Barclays PLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 122,849 shares of the specialty pharmaceutical company’s stock after buying an additional 14,061 shares during the period. Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $4,442,000 at […] - 2025-04-28 04:59:03
Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately […] - 2025-04-24 04:41:05
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.: Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of […] - 2025-04-20 05:22:48
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): JPMorgan Chase & Co. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,810 shares of the specialty pharmaceutical company’s stock after purchasing an additional 44,414 shares during the quarter. […] - 2025-04-15 04:32:48
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Arrowstreet Capital Limited Partnership increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,916 shares of the specialty pharmaceutical company’s stock after acquiring an additional 77,393 shares during […] - 2025-04-08 05:01:05
Prudential Financial Inc. Has $2.37 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Prudential Financial Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,733 shares of the specialty pharmaceutical company’s stock after buying an additional 8,352 shares […] - 2025-04-04 04:37:01
Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 296,915 shares of the specialty pharmaceutical company’s stock after selling 16,825 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $10,736,000 at the end of […] - 2025-03-30 05:37:02
Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. […] - 2025-03-26 05:44:46
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com: Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest […] - 2025-03-26 03:58:55

iShares Healthcare Innovation UCITS ETF USD (Acc) SUPN holdings

Date	Number of SUPN Shares Held	Base Market Value of SUPN Shares	Local Market Value of SUPN Shares	Change in SUPN Base Value	Current Price per SUPN Share Held	Previous Price per SUPN Share Held
2025-11-11 (Tuesday)	68,478	USD 3,157,521	USD 3,157,521	USD 48,620	USD 46.11	USD 45.4
2025-11-10 (Monday)	68,478	USD 3,108,901	USD 3,108,901	USD -42,457	USD 45.4	USD 46.02
2025-11-07 (Friday)	68,478	USD 3,151,358	USD 3,151,358	USD -85,255	USD 46.02	USD 47.265
2025-11-06 (Thursday)	68,478	USD 3,236,613	USD 3,236,613	USD 10,614	USD 47.265	USD 47.11
2025-11-05 (Wednesday)	68,478	USD 3,225,999	USD 3,225,999	USD -677,247	USD 47.11	USD 57
2025-11-04 (Tuesday)	68,478	USD 3,903,246	USD 3,903,246	USD 89,021	USD 57	USD 55.7
2025-11-03 (Monday)	68,478	USD 3,814,225	USD 3,814,225	USD 39,033	USD 55.7	USD 55.13
2025-10-31 (Friday)	68,478	USD 3,775,192	USD 3,775,192	USD -93,815	USD 55.13	USD 56.5
2025-10-30 (Thursday)	68,478	USD 3,869,007	USD 3,869,007	USD 56,152	USD 56.5	USD 55.68
2025-10-29 (Wednesday)	68,478	USD 3,812,855	USD 3,812,855	USD 171,880	USD 55.68	USD 53.17
2025-10-28 (Tuesday)	68,478	USD 3,640,975	USD 3,640,975	USD 30,815	USD 53.17	USD 52.72
2025-10-27 (Monday)	68,478	USD 3,610,160	USD 3,610,160	USD -7,533	USD 52.72	USD 52.83

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SUPN by Blackrock for IE00BYZK4776

Show aggregate share trades of SUPN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-10-24 SELL -580 52.830 53.280 53.235 USD -30,876 35.71 Loss of -10,166 on sale
2025-09-11 BUY 291 46.660 46.720 46.714 USD 13,594 34.15
2025-07-08 SELL -291 32.090 32.720 32.657 USD -9,503 33.86 Profit of 349 on sale
2025-06-24 SELL -293 31.670 32.670 32.570 USD -9,543 34.00 Profit of 420 on sale
2025-06-23 SELL -293 31.990 32.490 32.440 USD -9,505 34.02 Profit of 463 on sale
2025-06-20 BUY 2,257 32.280 33.300 33.198 USD 74,928 34.03
2025-06-11 SELL -282 33.150 33.660 33.609 USD -9,478 34.10 Profit of 140 on sale
2025-05-30 SELL -283 31.700 31.900 31.880 USD -9,022 34.21 Profit of 659 on sale
2025-05-21 BUY 283 32.630 33.160 33.107 USD 9,369 34.33
2025-05-14 SELL -1,692 31.540 32.350 32.269 USD -54,599 34.40 Profit of 3,598 on sale
2025-04-30 SELL -282 32.480 32.800 32.768 USD -9,241 34.62 Profit of 522 on sale
2025-04-28 SELL -282 32.250 32.570 32.538 USD -9,176 34.67 Profit of 600 on sale
2025-04-25 SELL -282 32.220 32.360 32.346 USD -9,122 34.69 Profit of 661 on sale
2025-04-11 SELL -1,704 31.670 31.680 31.679 USD -53,981 35.01 Profit of 5,684 on sale
2025-04-08 SELL -849 30.640 33.140 32.890 USD -27,924 35.15 Profit of 1,917 on sale
2025-04-07 SELL -598 32.270 34.260 34.061 USD -20,368 35.18 Profit of 670 on sale
2025-03-31 SELL -566 32.750 32.870 32.858 USD -18,598 35.31 Profit of 1,389 on sale
2025-03-21 SELL -564 32.150 32.900 32.825 USD -18,513 35.54 Profit of 1,529 on sale
2025-03-12 SELL -285 31.380 31.980 31.920 USD -9,097 35.91 Profit of 1,138 on sale
2025-02-28 SELL -285 32.060 32.080 32.078 USD -9,142 36.42 Profit of 1,239 on sale
2025-02-25 BUY 285 32.810 33.500 33.431 USD 9,528 36.64
2025-02-20 SELL -284 34.590 34.620 34.617 USD -9,831 36.82 Profit of 626 on sale
2025-02-19 BUY 568 33.520 35.360 35.176 USD 19,980 36.88
2025-02-18 BUY 284 39.750 39.990 39.966 USD 11,350 36.83
2024-12-30 BUY 1,726 36.910 37.280 37.243 USD 64,281 35.73
2024-12-06 SELL -273 37.170 37.480 37.449 USD -10,224 35.62 Loss of -499 on sale
2024-12-04 SELL -273 37.150 37.520 37.483 USD -10,233 35.52 Loss of -536 on sale
2024-12-03 SELL -546 37.030 37.240 37.219 USD -20,322 35.46 Loss of -959 on sale
2024-11-21 SELL -275 35.820 36.530 36.459 USD -10,026 35.02 Loss of -396 on sale
2024-11-20 SELL -280 36.120 36.500 36.462 USD -10,209 34.96 Loss of -421 on sale
2024-11-19 SELL -280 35.530 35.640 35.629 USD -9,976 34.92 Loss of -198 on sale
2024-11-18 SELL -1,096 35.250 36.200 36.105 USD -39,571 34.90 Loss of -1,317 on sale
2024-11-12 SELL -274 37.830 37.990 37.974 USD -10,405 34.71 Loss of -895 on sale
2024-11-07 SELL -274 36.400 37.750 37.615 USD -10,307 34.43 Loss of -872 on sale
2024-11-05 SELL -548 34.740 39.370 38.907 USD -21,321 34.10 Loss of -2,633 on sale
2024-10-28 SELL -274 34.160 34.680 34.628 USD -9,488 33.80 Loss of -228 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-24	SELL	-580	52.830	53.280	53.235	USD -30,876	35.71 Loss of -10,166 on sale
2025-09-11	BUY	291	46.660	46.720	46.714	USD 13,594	34.15
2025-07-08	SELL	-291	32.090	32.720	32.657	USD -9,503	33.86 Profit of 349 on sale
2025-06-24	SELL	-293	31.670	32.670	32.570	USD -9,543	34.00 Profit of 420 on sale
2025-06-23	SELL	-293	31.990	32.490	32.440	USD -9,505	34.02 Profit of 463 on sale
2025-06-20	BUY	2,257	32.280	33.300	33.198	USD 74,928	34.03
2025-06-11	SELL	-282	33.150	33.660	33.609	USD -9,478	34.10 Profit of 140 on sale
2025-05-30	SELL	-283	31.700	31.900	31.880	USD -9,022	34.21 Profit of 659 on sale
2025-05-21	BUY	283	32.630	33.160	33.107	USD 9,369	34.33
2025-05-14	SELL	-1,692	31.540	32.350	32.269	USD -54,599	34.40 Profit of 3,598 on sale
2025-04-30	SELL	-282	32.480	32.800	32.768	USD -9,241	34.62 Profit of 522 on sale
2025-04-28	SELL	-282	32.250	32.570	32.538	USD -9,176	34.67 Profit of 600 on sale
2025-04-25	SELL	-282	32.220	32.360	32.346	USD -9,122	34.69 Profit of 661 on sale
2025-04-11	SELL	-1,704	31.670	31.680	31.679	USD -53,981	35.01 Profit of 5,684 on sale
2025-04-08	SELL	-849	30.640	33.140	32.890	USD -27,924	35.15 Profit of 1,917 on sale
2025-04-07	SELL	-598	32.270	34.260	34.061	USD -20,368	35.18 Profit of 670 on sale
2025-03-31	SELL	-566	32.750	32.870	32.858	USD -18,598	35.31 Profit of 1,389 on sale
2025-03-21	SELL	-564	32.150	32.900	32.825	USD -18,513	35.54 Profit of 1,529 on sale
2025-03-12	SELL	-285	31.380	31.980	31.920	USD -9,097	35.91 Profit of 1,138 on sale
2025-02-28	SELL	-285	32.060	32.080	32.078	USD -9,142	36.42 Profit of 1,239 on sale
2025-02-25	BUY	285	32.810	33.500	33.431	USD 9,528	36.64
2025-02-20	SELL	-284	34.590	34.620	34.617	USD -9,831	36.82 Profit of 626 on sale
2025-02-19	BUY	568	33.520	35.360	35.176	USD 19,980	36.88
2025-02-18	BUY	284	39.750	39.990	39.966	USD 11,350	36.83
2024-12-30	BUY	1,726	36.910	37.280	37.243	USD 64,281	35.73
2024-12-06	SELL	-273	37.170	37.480	37.449	USD -10,224	35.62 Loss of -499 on sale
2024-12-04	SELL	-273	37.150	37.520	37.483	USD -10,233	35.52 Loss of -536 on sale
2024-12-03	SELL	-546	37.030	37.240	37.219	USD -20,322	35.46 Loss of -959 on sale
2024-11-21	SELL	-275	35.820	36.530	36.459	USD -10,026	35.02 Loss of -396 on sale
2024-11-20	SELL	-280	36.120	36.500	36.462	USD -10,209	34.96 Loss of -421 on sale
2024-11-19	SELL	-280	35.530	35.640	35.629	USD -9,976	34.92 Loss of -198 on sale
2024-11-18	SELL	-1,096	35.250	36.200	36.105	USD -39,571	34.90 Loss of -1,317 on sale
2024-11-12	SELL	-274	37.830	37.990	37.974	USD -10,405	34.71 Loss of -895 on sale
2024-11-07	SELL	-274	36.400	37.750	37.615	USD -10,307	34.43 Loss of -872 on sale
2024-11-05	SELL	-548	34.740	39.370	38.907	USD -21,321	34.10 Loss of -2,633 on sale
2024-10-28	SELL	-274	34.160	34.680	34.628	USD -9,488	33.80 Loss of -228 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SUPN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	122,151	3	301,188	40.6%
2025-09-18	121,761	0	267,525	45.5%
2025-09-17	70,393	750	204,211	34.5%
2025-09-16	92,803	0	275,024	33.7%
2025-09-15	117,876	210	292,580	40.3%
2025-09-12	56,904	200	164,689	34.6%
2025-09-11	80,785	50	192,706	41.9%
2025-09-10	97,206	0	247,182	39.3%
2025-09-09	103,403	21,544	214,675	48.2%
2025-09-08	94,030	1,712	217,571	43.2%
2025-09-05	65,260	300	193,611	33.7%
2025-09-04	87,479	9,555	199,603	43.8%
2025-09-03	71,553	1,695	171,333	41.8%
2025-09-02	151,600	32,060	318,698	47.6%
2025-08-29	78,344	2,289	147,467	53.1%
2025-08-28	96,124	974	162,328	59.2%
2025-08-27	98,424	4,105	244,875	40.2%
2025-08-26	68,382	0	134,610	50.8%
2025-08-25	114,093	2,502	258,415	44.2%
2025-08-22	170,458	7,565	320,385	53.2%
2025-08-21	126,877	1,383	256,896	49.4%
2025-08-20	97,552	696	267,866	36.4%
2025-08-19	96,500	5,963	208,444	46.3%
2025-08-18	104,771	1,006	285,510	36.7%
2025-08-15	124,036	20,531	334,977	37.0%
2025-08-14	83,036	4,471	360,725	23.0%
2025-08-13	143,796	4,486	408,810	35.2%
2025-08-12	120,422	909	359,231	33.5%
2025-08-11	112,810	6,919	330,272	34.2%
2025-08-08	228,449	58,762	395,640	57.7%
2025-08-07	334,014	0	923,644	36.2%
2025-08-06	692,071	6,110	1,667,362	41.5%
2025-08-05	248,650	0	476,509	52.2%
2025-08-04	162,989	0	229,997	70.9%
2025-08-01	250,179	0	326,684	76.6%
2025-07-31	433,277	375	912,336	47.5%
2025-07-30	158,360	5	215,826	73.4%
2025-07-29	188,561	0	455,538	41.4%
2025-07-28	160,930	0	241,816	66.6%
2025-07-25	98,853	0	302,328	32.7%
2025-07-24	122,057	0	194,071	62.9%
2025-07-23	62,190	0	125,509	49.6%
2025-07-22	141,516	1,325	343,162	41.2%
2025-07-21	197,089	0	471,962	41.8%
2025-07-18	105,706	0	300,279	35.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE